News >

Ongoing Studies May Clarify Role of ADCs in Gastric Cancer and CRC

Rachel Narozniak, MA
Published: Thursday, Feb 20, 2020

Jeremy Kortmansky, MD

Jeremy Kortmansky, MD

The approval of fam-trastuzumab deruxtecan-nxki (Enhertu) in HER2-positive breast cancer is generating hopes that similar strategies also may be effective against HER2-expressing gastric and colorectal cancers (CRCs), according to a panel of experts in gastrointestinal (GI) malignancies.

Click to Enlarge

“Interestingly, if you take patients who had prior irinotecan, the 43% response rate really does not change, suggesting that prior irinotecan does not necessarily dampen the effect of the ADC payload, including the nature of how it’s delivered,” Corcoran said.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication